Mechanism of Action
Lutein travels in the blood bound to lipoproteins, the carriers of fats. It then deposits in the retina, where two binding proteins hold it selectively. This sorting explains how a pigment present only in traces in food reaches a far higher concentration in the macula than in plasma.
Its structure carries a long chain of alternating double bonds. That chain absorbs light between 400 and 500 nm, the most energetic band of the visible spectrum, and gives it its yellow colour. This is an optical property of the molecule, measured in the laboratory.
The same chain reacts in the test tube with reactive oxygen species, those unstable molecules produced by metabolism. This is chemistry described in the laboratory, on the isolated molecule.
In humans, what is measured is the deposit: macular pigment optical density, read by flicker photometry or by fluorescence imaging. It rises slowly, over several months. Absorption depends on dietary fat, and taking it during a meal containing some favours passage into the circulation.
Key Benefits
- Moderate
A denser macular pigment: in adults with healthy eyes, a synthesis of forty-six studies (3,189 participants, mean age 43) measures optical density rising by 0.04 units between 5 and 20 mg per day of lutein and zeaxanthin, and by 0.11 units above 20 mg, over three to twelve months.
- Moderate
Vision returning faster after glare: in 115 young healthy adults, one year at 10 mg of lutein and 2 mg of zeaxanthin daily shortened recovery time versus placebo. Two meta-analyses confirm it, one of which puts the gain at 2.35 seconds.
- Moderate
Better discrimination of colour contrast: a placebo-controlled trial in 115 young healthy adults, on 10 mg of lutein and 2 mg of zeaxanthin daily for one year, measures improved chromatic contrast.
- Emerging
A more favourable lipid profile: in 117 adults with abdominal adiposity, 10 mg of lutein daily for 32 weeks lowered total cholesterol, LDL cholesterol and apolipoprotein B versus placebo. A single trial to date.
Dosage & Forms
Two forms coexist on the market: free lutein, described as non-esterified, and lutein esterified to fatty acids. Which of the two is absorbed better long divided the literature. A 2024 crossover trial settled it by giving 6 mg per day of each form, drawn from the same marigold extract, to twenty-four adults for two months: the serum response is identical.
Trial doses are read on the lutein plus zeaxanthin total, since the two arrive together. Below 5 mg per day, the synthesis of forty-six studies records no clear change in macular pigment. Its 5 to 20 mg stratum measures a gain of 0.04 optical density units, and its above 20 mg stratum a gain of 0.11 units. Its meta-regression, across eighteen placebo-controlled trials, places the progression at 0.003 units per additional daily milligram.
Observed durations run from three to twelve months, the time the deposit needs to reach its plateau. On safety, a published risk assessment retains 20 mg of lutein per day as the level up to which the data are solid.
In the Singular Formula
Inclusion rationale
Carotenoid of the xanthophyll family, extracted from marigold petals (Tagetes erecta). Lutein concentrates in the macula of the retina, at the periphery of the fovea, where it forms the macular pigment together with zeaxanthin. The two travel together: the same raw material supplies them in the 5:1 ratio of our diet, which is also the one administered in the reference trials. The structure of the molecule absorbs light between 400 and 500 nm, an optical property measured in the laboratory that gives it its yellow colour. The density of this pigment is measured in humans without any sampling, and it rises with intake: this is the quantity on which most trials rest, and it increases with dose. The body does not synthesise lutein. Dietary intakes recorded in European adults remain well below the doses used in trials.
Selected form
XanMax® 2505 is a Tagetes erecta flower extract produced at a 400:1 extraction ratio and standardised to at least 25% lutein and 5% zeaxanthin. Lutein is a carotenoid of the xanthophyll family that naturally concentrates in the macula, the central area of the retina responsible for fine vision. The human body cannot synthesise it, so it must be obtained through the diet.
Formula dosage
0 to 20 mg.
Dose expressed as active substance, excluding excipients and carriers of the raw material.
Synergies in the formula
Linked Biomarkers
Safety & Precautions
Lutein has a long record of use. The AREDS2 trial followed more than four thousand adults for five years on 10 mg of lutein and 2 mg of zeaxanthin, with no notable adverse effect attributed to that combination.
Safety assessments leave wide margins. The acceptable daily intake set by the European authority for marigold lutein corresponds to about 60 mg per day in a 60 kg adult. A published risk assessment separately retains 20 mg per day as the level up to which the safety data are solid.
Prolonged carotenoid supplementation can give the skin a yellowish tint known as carotenodermia. The phenomenon is benign and fades on stopping.
Lutein is not converted to vitamin A by the body, which rules out the accumulation risk specific to retinol. No notable drug interaction is documented. Medicines that reduce fat absorption may also reduce carotenoid absorption. During pregnancy or breastfeeding, the formula limits lutein to 10 mg per day. The same raw material then supplies approximately 2 mg of zeaxanthin.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Wilson LM et al. | 2021 | Meta-analysis | Advances in Nutrition | View on PubMed |
The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis Forty-six studies, 3,189 adults with healthy eyes, results stratified by dose. Below 5 mg per day, no clear change. From 5 to 20 mg, macular pigment density gains 0.04 units; above 20 mg, 0.11 units. The meta-regression across eighteen placebo-controlled trials gives 0.003 units per daily milligram. Strength of evidence rated moderate by the authors. | ||||
| Hammond BR et al. | 2014 | Randomised Controlled Trial | Investigative Ophthalmology & Visual Science | View on PubMed |
A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast One hundred and fifteen young healthy adults, 10 mg of lutein and 2 mg of zeaxanthin daily for one year. Chromatic contrast and photostress recovery time improved versus placebo, and macular pigment density rose at every eccentricity measured. Glare disability, however, did not change significantly in the supplemented group. | ||||
| Obana A et al. | 2015 | Randomised Controlled Trial | PLoS One | View on PubMed |
Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements Thirty-six healthy volunteers, randomised double-masked between two marigold extracts supplying about 10 mg of lutein per day, one of them XanMax®, the material selected by Singular. After six months serum lutein rose, but mean macular pigment density did not increase significantly in either group, and contrast sensitivity stayed flat. The trial compares two products with no placebo arm, on eighteen subjects per group. Participants whose pigment was lowest at baseline are the ones in whom it rose. | ||||
| Hu W et al. | 2024 | Meta-analysis | Advances in Nutrition | View on PubMed |
Effect of Antioxidant Supplementation on Macular Pigment Optical Density and Visual Functions: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials Thirty-eight controlled trials compared in a network. Every supplemented group raised macular pigment density and contrast at low spatial frequency, with no gain at normal or high frequencies. The lutein plus zeaxanthin combination is the only one to significantly shorten photostress recovery time. The authors rate the quality of evidence as low. | ||||
| Hu W et al. | 2023 | Meta-analysis | Nutrition Reviews | View on PubMed |
Effect of xanthophyll-rich food and supplement intake on visual outcomes in healthy adults and those with eye disease: a systematic review, meta-analysis, and meta-regression of randomized controlled trials Forty-three articles retained, twenty-five pooled. Xanthophyll intake raises macular pigment density by both measurement methods and shortens photostress recovery time by 2.35 seconds. The visual acuity gain appears only in people with an eye condition, not in adults with healthy sight. | ||||
| Zhou J et al. | 2025 | Randomised Controlled Trial | Food & Function | View on PubMed |
Effect of lutein supplementation on blood lipids and advanced glycation end products in adults with central obesity: a double-blind randomized controlled trial One hundred and seventeen adults with abdominal adiposity, 10 mg of lutein daily for 32 weeks against placebo. Plasma total cholesterol, LDL cholesterol, apolipoprotein B and malondialdehyde fell in the supplemented group, as did three advanced glycation end products. | ||||
| Age-Related Eye Disease Study 2 Research Group | 2013 | Randomised Controlled Trial | JAMA | View on PubMed |
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial Four thousand two hundred and three adults aged 50 to 85, five years of follow-up, 10 mg of lutein and 2 mg of zeaxanthin added to the formulation all participants received. The primary analysis did not reach significance on progression to the advanced form (HR 0.90; P = 0.12). The contribution of the trial lies elsewhere: it allowed beta-carotene to be replaced, its follow-up having shown an excess lung cancer risk in former smokers. | ||||
| Olmedilla-Alonso B et al. | 2024 | Randomised Controlled Trial | Nutrients | View on PubMed |
Bioavailability of Lutein from Marigold Flowers (Free vs. Ester Forms): A Randomised Cross-Over Study to Assess Serum Response and Visual Contrast Threshold in Adults Twenty-four adults, crossover trial, 6 mg of lutein per day for two months in free then esterified form, drawn from the same marigold extract. Serum lutein rose 2.4-fold within fifteen days, with no difference between the two forms at any point in the trial. | ||||